Moleculin Biotech ( ($MBRX) ) has shared an announcement. On December 9, 2025, Moleculin Biotech, Inc. entered into inducement offer agreements ...

Management has positioned bezuclastinib as a potential alternative to Blueprint Medicines' (BPMT) Ayvakit. This PDGFRα/c-KIT ...

AI powers digital twins of cells/molecules, speeding early drug discovery and cutting trial-and-error work. Read more here.

Clearmind Medicine shares dropped in after-hours trading following the company's announcement of a 1-for-40 reverse stock ...

Amid a challenging climate for Vancouver’s life sciences sector, Zymeworks Inc. (Nasdaq:ZYME) stands out as a success story ...

Capricor Therapeutics (CAPR) stock is the best stock on Wall Street and burning short sellers after upbeat drug data ...

This biotech company has implanted a heart device as part of a clinical trial looking to open up new markets. The post ...

But sometimes, this top investor who focuses on innovation does see eye-to-eye with analysts, and the perfect example of this ...

Boqii shares surged in after-hours trading following the announcement of a $1.76 million equity repurchase by the founders of ...

Argenica Therapeutics shares have surged higher after positive clinical trial results for its stroke treatment drug.

Wave Life Sciences' shares fell sharply after the clinical-stage biotechnology company priced an upsized $350 million equity raising. The shares were down 10% at $19.09 in early trading Wednesday, ...

Structure's aleniglipron elicited over 11% weight loss in a Phase II trial, sending the biotech's stock up nearly 103% as ...